Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Fiche publication

Date publication

juillet 2026

Journal

Translational oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel , Dr FAVIER Laure , Dr KAMINSKY Marie-Christine

Tous les auteurs :
Corbaux P, Colomban O, Lescuyer G, Ray-Coquard I, De Rauglaudre G, Joly F, Abdeddaim C, Combe P, Blonz C, Bataillon G, Meunier J, Alexandre J, Berton D, Kaminsky MC, Bello Roufai D, Leary A, Venat L, Dohollou N, Louvet C, Lebreton C, Abadie-Lacourtoisie S, Lotz JP, Favier L, Fabbro M, Bonichon-Lamichhane N, Kurtz JE, Follana P, Pujade-Lauraine E, Payen L, You B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42385345

Résumé

Circulating nucleosomes (DNA wound around histone proteins) are emerging cancer biomarkers. We investigated their association with clinical outcomes in advanced ovarian cancer.